Nya antivirala läkemedel mot hepatit C i kliniska studier

Lakartidningen

Volumn 106, Issue 48, 2009, Pages 3254-3260

  Lennerstrand, Johan ^c   Bondeson, Kåre ^c   Bergqvist, Anders ^c   Blomberg, Jonas ^a   Öberg, Bo ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b MEDIVIR AB   (Sweden)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; FUSED HETEROCYCLIC RINGS; N (17 (2 (4 ISOPROPYLTHIAZOLE 2 YL) 7 METHOXY 8 METHYLQUINOLIN 4 YLOXY) 13 METHYL 2,14 DIOXO 3,13 DIAZATRICYCLO(13.3.0.04,6)OCTADEC 7 ENE 4 CARBONYL)(CYCLOPROPYL)SULFONAMIDE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(17-(2-(4-ISOPROPYLTHIAZOLE-2-YL)-7-METHOXY-8-METHYLQUINOLIN-4-YLOXY)-13-METHYL-2,14-DIOXO-3,13-DIAZATRICYCLO(13.3.0.04,6)OCTADEC-7-ENE-4-CARBONYL)(CYCLOPROPYL)SULFONAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; SULFONAMIDE; TELAPREVIR; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CHEMISTRY; DRUG APPROVAL; DRUG COMBINATION; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG APPROVAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; SULFONAMIDES; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 71449088499     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 1998;351(9096):83-7.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
3. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000;6 (12):1375-9.
4. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20(1):23-38.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.
6. Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, et al. Lower-thanstandard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weightbased ribavirin. J Viral Hepat. 2008;15(9):641-5.
7. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5(6):453-63.
8. Koev G, Kati W. The emerging field of HCV drug resistance. Expert Opin Investig Drugs. 2008;17(3): 303-19.
9. Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ. Approaches for the development of antiviral compounds: the case of hepatitis C virus. Handb Exp Pharmacol. 2009; (189):25-51.
10. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, Thomson M, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology. 2007;132(5):1757-66.
11. Shi ST, Herlihy KJ, Graham JP, Fuhrman SA, Doan C, Parge H, et al. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother. 2008;52(2):675-83.
12. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008;198(6): 800-7.
13. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008;48(6): 1769-78.
14. He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother. 2008;52(3):1101-10.
15. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology. 2009;49(4): 1069-82.
16. Mondelli MU, Cerino A, Segagni L, Meola A, Cividini A, Silini E, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res. 2001;52(2):153-9.
17. Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol. 2007;13(36):4839-47.
18. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-50.
19. Kwo P, Lawitz E, McCone J, Schiff J, Vierling D, Pound M, et al. RVR/EVR from phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with HCV genotype1 CHC. J Hepatol. 2008; 48(Suppl 2):372.
20. Läkemedelsbehandling av kronisk hepatit C hos vuxna och barn. Uppdaterad rekommendation. Information från Läkemedelsverket. 2008:(19)6:14-52.